¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Newsletter (Infant Feeding Action Coalition)."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • feeding jejunostomy
    ±Þ½ÄºóâÀÚ⳿(¼ú), ±Þ½Ä°øÀåÁ¶·ç(¼ú)
  • forced feeding
    °­Á¦¿µ¾ç
  • gastric feeding
    À§¿µ¾ç, À§±Þ½Ä
  • intravenous feeding
    Á¤¸Æ¿µ¾ç°ø±Þ
  • maternal feeding
    ¸ðÀ¯¿µ¾ç
  • nasal feeding
    ÄÚ°æÀ¯¿µ¾ç(¹ý)
  • parenteral feeding
    ºñ°æ±¸¿µ¾ç(¹ý)
  • school feeding
    Çб³±Þ½Ä
  • supplementary feeding
    º¸Á¶¿µ¾ç
  • self-demand feeding
    ºÒ±ÔÄ¢¼öÀ¯, Àھƿ屸¼öÀ¯
  • sham feeding
    Çê±Þ½Ä
  • antifungal action
    Ç×Áø±ÕÀÛ¿ë
  • antimicrobial action
    Ç×±ÕÀÛ¿ë
  • antipyretic action
    ÇØ¿­ÀÛ¿ë
  • action
    1. ÀÛ¿ë 2. Ȱµ¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • feeding
    ¿µ¾ç, ±Þ½Ä
  • feeding formula
    ½Ä»çó¹æ, ±Þ½Äó¹æ
  • feeding gastrostomy
    ¿µ¾çÀ§Ã¢³¿¼ú, ±Þ¾çÀ§Á¶·ç¼ú
  • feeding
    ±Þ½ÄºóâÀÚ⳿¼ú, ±Þ½Ä°øÀå⳿¼ú
  • forced feeding
    °­Á¦¿µ¾ç
  • intravenous feeding
    Á¤¸Æ¿µ¾çº¸±Þ
  • maternal feeding
    ¸ðÀ¯¿µ¾ç
  • nasal feeding
    °æºñ¿µ¾ç¹ý, ÄÚ±Þ½Ä
  • school feeding
    Çб³±Þ½Ä
  • self-demand feeding
    ºÒ±ÔÄ¢¼öÀ¯, Àھƿ屸¼öÀ¯
  • sham feeding
    Çê±Þ½Ä
  • supplementary feeding
    º¸Á¶¿µ¾ç
  • tube feeding
    Æ©ºê¿µ¾ç
  • action
    Ȱµ¿, ÀÛ¿ë
  • absorption action
    Èí¼öÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • SDA= specific dynamic action
    ƯÀ̵¿Àû ÀÛ¿ë.
  • absorption action
    Èí¼öÀÛ¿ë.
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø)
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø).
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
  • action tremor
    ÇàÀ§ÁøÀü(ú¼êÓòÉïµ).
  • action, bactericidal
    »ì±ÕÀÛ¿ë
  • action, bacteriostatic
    Á¤±ÕÀÛ¿ë
  • additive action
    ºÎ°¡ÀÛ¿ë.
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • after action
    ÈÄ(¼Ó)(ý­(áÙ))ÀÛ¿ë.
  • amphoteric action
    ¾ç¼ºÀÛ¿ë.
  • anabolic action
    (´Ü¹é)µ¿È­ÀÛ¿ë(Ó±ÛÜÔÒûùíÂéÄ)
  • analgesic action
    ÁøÅëÀÛ¿ë(òå÷ÔíÂéÄ).
  • anesthetic action
    ¸¶ÃëÀÛ¿ë(¡­íÂéÄ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • supplementary feeding
    º¸Ã濵¾ç¹ý(ÜÍõöç½å×Ûö).
  • tube feeding
    °æ°ü½ÄÀ̹ý(ÌèηãÝìÈÛö), °ü¿µ¾ç(ηç½å×).
  • floppy infant
    ±Ù±äÀå ÀúÇϾÆ
  • floppy infant =flopping i.
    ±Ù±äÀåÀúÇϾÆ(ÐÉÑÌíåî¸ù»ä®).
  • high risk infant
    °íÀ§Ç輺 ¿µ¾Æ.
  • idiopathic respiratory distress of newborn infant =IRDNI
    ½Å»ý¾ÆÆ¯¹ß¼º È£Èí°ï¶õÁõ.
  • immature infant
    ¹Ì¼÷¾Æ(Ú±âÙä®).
  • infant
    ¿µ¾Æ(¿µä®)
  • infant at full term =t. f.
    ¸¸±â»ê¾Æ(ػѢ ß§ä®).
  • infant botulism
    À¯¾Æº¸Åø¸®´®Áõ
  • infant circle
    À¯¾Æ¿ë ¼øÈ¯(½Ä)ȸ·Î, ¼Ò¾Æ¼øÈ¯È¸·Î.
  • infant day care
    ¿µ¾Æ ÁÖ°£ °¡·á
  • infant death statistics
    ¿µ¾Æ»ç¸ÁÅë°è(?ä®ÞÝØÌ÷Öͪ).
  • infant death statistics
    ¿µ¾Æ»ç¸ÁÅë°è(ÊþËâË×ËÎ̬˭).
  • infant feedings
    ¿µ¾Æ¿µ¾ç(?ä®ç½å×).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
fdg feeding
HCF [fetal] head-to-cervix force; heparin cofactor; hereditary capillary fragility; highest common facto...
HPF heparin-precipitable fraction; hepatic plasma flow; high-pass filter; high-power field [microscope];...
HTB house tube feeding; human tumor bank
HTF heterothyrotropic factor; house tube feeding; HpaII tiny fragment
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SGA small for gestational age infant
VLBWI very low birth weight infant
AP Action Potential
APA Action potential amplitude
APD Action potential duration
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antidiuretic action
    Ç×ÀÌ´¢ÀÛ¿ë
  • antimicrobial action
    Ç×±Õ ÀÛ¿ë
  • antinociception action
    Ç×Ä§ÇØ¼ö¿ë¼º ÀÛ¿ë, Ç×À¯ÇØ ¼ö¿ë¼º ÀÛ¿ë
  • antipyretic action
    ÇØ¿­ ÀÛ¿ë
  • antispasmodic action
    Áø°æÀÛ¿ë
  • bactericidal action
    »ì±Õ ÀÛ¿ë, »ì±Õ¼º
    1. ¹ÚÅ׸®¾Æ¸¦ Á×ÀÌ´Â Çö»ó. ÀÌ ¿ë¾î´Â Á¾Á¾ Ç×»ýÁ¦ÀÇ ¼º°ÝÀ» ¼³¸íÇϴµ¥ »ç¿ëµÈ´Ù. 2. È­Çпä¹ýÁ¦, ¼Òµ¶Á¦ Áß¿¡´Â ¹Ì»ý¹°À» ¼Ò¸ê½ÃŰ´Â ÀÛ¿ëÀÌ ÀÖ´Ù. ÀÌ¿¡ ´ëÇØ ¾î¶² ¾àÁ¦¿¡ ´ëÇØ ±ÕÀÇ Áõ½ÄÀÌ ¾ïÁ¦µÇ´Âµ¥ ¾àÁ¦¸¦ Á¦°ÅÇÏ¸é ´Ù½Ã Áõ½ÄÇÏ´Â °ÍÀ» Áõ±Õ ÀÛ¿ëÀ̶ó ÇÑ´Ù.
  • bacteriostatic action
    Á¤±Õ ÀÛ¿ë
    ¼¼±ÕÀÇ ¹ßÀ° ¶Ç´Â Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ÀÛ¿ë.
  • biological action
    »ý¹° ÀÛ¿ë
  • buffer action
    ¿ÏÃæ ÀÛ¿ë
  • calorigenic action
    ¿­ »ý»ê ÀÛ¿ë
    À½½Ä¹° ¶Ç´Â À½½Ä¹° ¼ººÐ¿¡ ÀÇÇØ ü³»¿¡ ¹ß»ýÇÑ ÃÑ ¿¡³ÊÁö·®.
  • cause of action
    ¼Ò¼ÛÀÇ ¿øÀÎ
    ´ëºÎºÐ, ¹ýÀû Á¶Ä¡ÀÇ ¹è°æÀ̳ª ÀÌÀ¯¸¦ ÀǹÌÇÑ´Ù. ¹ýÀû ¹è»óÀ» ÇÏ¿©¾ß ÇÏ´Â À߸øµÈ ¿øÀÎ.
  • central action
    ÁßÃß ÀÛ¿ë
  • chronotropic action
    º¯µ¿ ÀÛ¿ë, º¯½Ã ÀÛ¿ë
  • ciliary action
    ¼¶¸ð ÀÛ¿ë
  • cleaning action
    ¼¼Á¤ ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
sparing action The manner in which a nonessential nutritive component, by its presence in the diet, lowers the dietary requirement for an essential component; thus, nonessential l-cysteine spares essential l-methionine and nonessential l-tyrosine spares essential l-phenylalanine.
Synonym: sparing phenomenon.
(05 Mar 2000)
specific action The action of a drug or a method of treatment which has a direct and especially curative effect upon a disease, e.g., the action of vitamin B12 in pernicious anaemia.
(05 Mar 2000)
specific dynamic action The increase of heat production caused by the ingestion of food, especially of protein.
(05 Mar 2000)
delayed-action preparations Dosage forms of a drug that act over a period of time.
(12 Dec 1998)
thermogenic action Increase of heat production of the body, as by the thyroid hormone.
Synonym: thermogenic action.
(05 Mar 2000)
law of mass action <chemistry> This law states that the rate of a given chemical reaction is proportional to concentration of the reactants.
(09 Oct 1997)
Bayley Scales of Infant Development A psychological test used to measure the developmental progress of infants over the first two and one-half years of life; consists of three scales: mental, motor, and behaviour record.
(05 Mar 2000)
rate, infant mortality The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
Cattell Infant Intelligence Scale A standardised scale for assessment of the cognitive development of infants between the ages of 3 and 30 months.
(05 Mar 2000)
mortality rate, infant The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
postmature infant A baby born 1 week (7 days) or more after the usual 9 months (280 days) of gestation.
(12 Dec 1998)
post-term infant A baby born 2 weeks (14 days) or more after the usual 9 months (280 days) of gestation, as calculated from the last menstrual period (lmp). This is an important calculation, since, if delivery is delayed 3 weeks beyond term, the infant mortality rate skyrockets to 3 times normal.
(12 Dec 1998)
preterm infant An infant with gestational age of less than 37 completed weeks (259 completed days).
(05 Mar 2000)
stillborn infant An infant who shows no evidence of life after birth.
Compare: liveborn infant.
(05 Mar 2000)
sudden infant death The abrupt and unexplained death of an apparently healthy infant under one year of age, remaining unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of the clinical history. (expert panel of the national institute of child health and human development in paediatric pathology, v.11, no.5, sept-oct 1991, p681)
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • real action
    ´ë¹° ¼Ò¼Û(¹°°Ç ÀÚüÀÇ È¸º¹À» û±¸ÇÏ´Â)
  • rear-guard action
    Áö¿¬ ÀÛÀü;¼ÓÀÌ´Â(µûµ¹¸®´Â)Çൿ(Àü¼ú) V
  • reflex action
    ¹Ý»ç ÀÛ¿ë
  • shock action
    Ãæ°Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á